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Atrial fibrillation represents the most common, highly
prevalent cardiac arrhythmia which is the strongest risk fac-
tor for ischemic stroke, affecting millions of people. 
Effective anticoagulation therapy is associated with de-
creased stroke severity, improved functional outcome, and
better survival in patients with AF admitted with acute brain
ischemia. 
Several risk stratification schemes such as CHADS2 score,
CHA2DS2-VASc score, or HAS-BLED are used. 
Patients with AF <65 years of age and no other risk factors
have a minimal benefit from warfarin as compared to no
therapy, due to the low underlying risk of stroke.It is in-
creasingly evident that treatment decisions have to be based
on individual risk assessment. 
Although we are all aware of devastating consequences of
stroke, a large number of patients are still left untreated. On
average 30% out of possible 60-70% of patients are treated
with oral anticoagulation.
Because of the limitations of old oral anticoagulants, as well
as parenteral anticoagulants which are not suitable for long-
tern therapy, our hopes are set towards new oral anticoagu-
lants without the need for constant coagulation monitoring.
New oral anticoagulants include oral thrombin inhibitors
and oral factor Xa inhibitors. Among thrombin inhibitors
we have dabigatranetexilate, a prodrug of dabigatran, which
reversibly inhibits the active site of thrombin. Peak plasma
levels are reached 0.5 to 2 hours after administration of sin-
gle dose. Dabigatran’s half-life is 14 to 17 hours, which
makes it suitable for once or twice daily administration and
about 80% of the drug is secreted by kidneys unchanged.
Among oral factor Xa inhibitors, progressively investigated
are rivaroxaban, apixaban, and edoxaban. Factor Xa in-
hibitors bind reversibly to active sites of fXa. Rivaroxaban is
an active compound with oral availability of about 80%,
with rapid onset of action and a half-life of 7 to 11 hours.
Elimination of the compound can be prolonged in elderly
patients.
Apixaban is an active drug, rapidly absorbed, reaching max-
imal plasma concentrations after 3 hours, and having a half-
life of 8 to 14 hours. It is eliminated through multiple
pathways, the hepatic metabolism via CYP3A4, renal and
intestinal excretion.
Edoxaban is an active drug, rapidly absorbed, with a half-life
of 9 to 11 hours. Approximately one third of the drug is
eliminated through the kidney, while the rest is excreted by
feces.
The need for anticoagulants which are simpler to adminis-
ter than vitamin K antagonists, will soon be resolved by
availability of new oral anticoagulants.
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